Five separate states have filed insulin pricing scheme lawsuits against drug manufacturers, and are calling for the cases to be consolidated in a Mississippi federal court.
Lawsuits allege the insulin pricing scheme leads to states and consumers paying $300 to $700 for doses, which cost the drug makers just $2 to produce.
Rebates disguised as "administrative fees" and other costs lead to an illegal insulin pricing scheme which costs consumers and the healthcare system billions of dollars, the lawsuit claims
The manufacturer also expects the FDA to reject approval for the drug for the treatment of atopic dermatitis due to FDA safety cocerns.
Cancer and heart risks linked to Rinvoq, Xeljanz and similar drugs have regulated them to secondary treatment options for rheumatoid arthritis.
Study claims heart risks with Olumiant are the same as those of rheumatoid arthritis patients not taking the drug, raising questions about a class-wide warning after concerns about the side effects of Xeljanz emerged
More research is needed into the link between Xeljanz and heart problems to determine how much of the risk is caused by side effects of the drugs, or the condition they are designed to treat, the researchers note
